Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?



IPO Report: Intrexon (XON)

By  +Follow August 7, 2013 11:03AM
Tickers Mentioned:

Nine other IPOs were scheduled for the week of August 5. The full IPO calendar can be found at IPOpremium.

Intrexon ($XON) is based in Germantown, MD.  XON scheduled a $124 million IPO with a market capitalization of $1.4 billion at a price range mid-point of $15, for Thursday, August 8, 2013.

The price range was set in theS-1 filed July 29, 2013.  The manager and joint manager are J.P. Morgan & Barclays.  The co-managers are Griffin Securities & Mizuho Securities


XON believes it is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems.

Q1 '13 $4 million in revenue with a $36 million loss.

One person owns 71%, apparently no venture capitalists, and no collaborators are investors. No patents, yet.

XON is bringing its technology to the market through collaborations, of which there are currently nine. Two are private companies and seven are public. The only large collaborator is Elanco, the animal health division of Eli Lilly and Company (LLY) , $57 billion market capitalization.

The rest are mostly micro cap companies, two of which have contributed stock to XON in return for the technology.

XON has an accumulated deficit of $363 million, and has raised $559 million to-date. Not entirely clear where that $559 million came from.


Valuation Ratios

IPO Mrkt

Price /

Price /

Price /

Price /

% offered

annualizing Q1 '13

Cap (mm)





in IPO

Intrexon ($XON)








Only 9% is being offered on the IPO, a surprisingly small amount for a company that lost $36 million in Q1 '13. XON is IPO'ing at 4.3 times book, which seems reasonable


The rating is buy because if the technology is for real then XON could be a big stock. $559 million has been invested in the past several years, which is an indication some investors have done their due diligence, and 4.3 times book value is in range for this kind of company.

To put the conclusions and observations in context, the following is reorganized, edited, and summarized from the full S-1 referenced above:


XON believes it is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems.

Synthetic biology aims to engineer gene-based programs or codes to modify cellular function to achieve a desired biological outcome. For example, applications may include the replacement of a defective protein with a functional protein to treat a broad range of human and animal disease states, or the production of multiple proteins through the regulation of several genes in a cell to produce petrochemicals.

Using proprietary and complementary technologies, XON designs, builds and regulates gene programs, which are DNA sequences that consist of key genetic components.

A single gene program or a complex, multi-genic program are fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information.

DNA vectors can, in turn, be introduced into cells in order to generate a simple or complex cellular system, which are the basic and complex cellular activities that take place within a cell and the interaction of those systems in the greater cellular environment.

It is these genetically modified cell systems that can be used to produce proteins, produce small molecules, or serve as cell-based products, which enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences.

Intrexon's synthetic biology capabilities include the ability to precisely control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Exclusive Channel Collaborations (ECCs)

XON provides expertise in the engineering, creation and modification of gene programs and cellular systems, and collaborators are responsible for providing market and product development expertise, as well as regulatory, sales and marketing capabilities.

Generally, the collaborators compensate XON through payment of technology access fees, royalties, milestones and reimbursement of certain costs.

Nine ECC agreements

XON began entering into ECCs in 2011 and are currently party to nine such agreements.

Under these ECCs, XON is developing products in the fields of healthcare and food. In healthcare, ECCs include programs in oncology, anti-infectives, antibiotics and tissue repair.

In food, XON is working to increase the productivity and nutritional value of salmon and other fish. XON is are also working to establish ECCs in the areas of energy and environmental sciences.

Seven ECC companies are public

Except for Elanco (Eli Lilly division) the companies are all micro caps. The largest market cap is ZIOP, with a market cap of $249 million.

If the technology is to be worth $1.4 billion XON's IPO, then XON should have larger, better known collaborators receiving exclusives.


Effective January 6, 2011, XON entered into an ECC with ZIOPHARM Oncology, Inc. (ZIOP) , or ZIOPHARM, $249 million market capitalization.


Effective November 28, 2011, XON entered into an ECC with Elanco, the animal health division of Eli Lilly and Company (LLY) , $57 billion market capitalization.


Effective October 5, 2012, we entered into an ECC with Fibrocell Science, Inc. (FCSC) , $130 market capitalization.


Effective June 5, 2012, XON entered into an ECC with Oragenics, Inc. (OGEN) , $86 million market capitalization.

Synthetic Biologics

Effective August 6, 2012, XON entered into an ECC with Synthetic Biologics, Inc. (SYN) , $68 million market cap.


AquaBounty Technologies, Inc. ($ABTX), $45 million market cap. XON also owns 54% of ABTX, as of Mach 15, 2013.


Effective March 29, 2013, XON entered into an ECC with AmpliPhi BioSciences Corp. (APHB) , $11 million market cap. XON received 24 million shares as an upfront access fee.


Effective April 27, 2013, XON entered into an ECC with Soligenix, Inc. ($SNGX), $20 million market cap. XON received 1 million shares as an upfront technology access fee.

XON also entered into agreements with two private companies


Synthetic biology has applicability across many diverse end markets.


  Therapeutics. Both in human health and animal health, synthetic biology has the potential to enable the development of highly complex biological molecules as well as the ability to regulate complex biological processes, with advantages as compared to traditional therapeutics, both in vivo and ex vivo. It may be possible, for example, to create highly targeted precision therapeutics with few off-target or adverse effects.

  Bioproduction Synthetic biology allows new biologically based manufacturing techniques that have the potential to significantly lower the cost of goods for highly complex biological molecules, including both existing and novel biopharmaceuticals as well as small molecules.

  Diagnostics By utilizing the sensing and reporting capabilities of cells and specific cellular mechanisms, it may be possible to create highly sensitive diagnostics, to report on a patient's health and provide advance warning of changes in the state of the patient's health.


  Food animals By applying its suite of technologies, XON believes it can more rapidly develop livestock with commercially valuable attributes such as enhanced nutritional content, resistance to disease and increased growth efficiency.

  Agriculture XON believes that it can use gene expression and gene regulation technologies to provide highly complex traits related to enhanced nutritional content, product quality and disease resistance.

Energy and chemicals

  Energy XON has already achieved as proof of concept the conversion by engineered bacteria of methane to isobutanol, which is an alternative alcohol-based fuel.

  Chemicals Economically viable alternatives to carbon feed stocks are critical to the future and sustainability of the chemical industry.

Environmental sciences

  Biosensors The biosensor global market is forecasted to exceed $12 billion by 2016 and opportunities exist to capture a portion of this market through design and construction of unique biosensors that leverage XON's suite of proprietary and complementary technologies.

  Bioremediation The global market for microbial and associated bioremediation products is forecasted to reach over $1 billion by 2016. Industrial sources of soil and groundwater contamination present major environmental, policy and health issues because of the adverse effects of contaminants on humans and ecosystems. Bioremediation, which XON believes its technologies have the potential to enable, can provide an environmentally friendly, socially acceptable, effective and economically viable solution.

  Specialty Processes XON believes its suite of proprietary and complementary technologies has the potential to be used to introduce effective solutions for applications such as activated microbial filtration, waterborne pathogen elimination, and de-nitrification of waste and surface water.

XON's approch

The essence of XON's approach is to apply synthetic biology by using an iterative process that is rapid, automated and highly reproducible, in which we:

Design genes of interest and gene programs utilizing knowledge of cellular pathways and protein function;

Build biological molecules, gene programs and their variants to optimize performance of the biological system;

Test gene programs by inserting them into cellular systems and comparing the result(s) to the intended effects; and

Learn by utilizing information gained in our iterative processes to create better DNA vectors and gene programs using a more informed and efficient process to achieve improved outcomes.

As a result of its approach, XON has developed extensive knowledge about many classes of DNA components and the rules governing their expression and activity. XON has also assembled an inventory of these DNA components that XON can use to rationally construct unique vectors rapidly and with predictable outcomes. The knowledge embedded in XON's DNA database allows XON to create single gene and highly complex multigenic gene programs (an individual gene program containing multiple genes).

Integrated technologies

To support the design-build-test-learn approach, XON developed a unique suite of technologies. These technologies are complementary in nature and share the following key characteristics:

Platform neutral - outcome oriented.

Knowledge driven.

Rationally designed. XON's knowledge of biological systems and components allows XON to design, build and select gene programs and predict the probable outcome of these programs.

Capable of complexity. XON's technologies enable the design and precise control of complex biological molecules and multigenic gene programs.

Industrial scale. XON uses engineering principles and automation to enable products based on synthetic biology that are commercially viable.

Intellectual property

XON seeks patent protection for its platform technologies.


XON does not believe that it has any direct competitors who provide similar technologies which fully enable the commercialization of products developed using synthetic biology across a broad spectrum of biologically based industries. As a result, XON believes its competition is more indirect and general in nature, and falls into three broad categories:

• Synthetic biology service providers
There are companies that have competing technologies for individual pieces of XONs suite of complementary technologies. XON believes the following companies engage in the manufacture of DNA componentry: DNA 2.0, Inc., Blue Heron Biotech, LLC and Life Technologies Corporation. Another portion of our proprietary technology includes development of fully human monoclonal antibodies.

XON's technology utilizes advanced methods of stimulating antibody production in naïve human B-cells in vitro and specifically selecting those cells which produce antibodies that can bind a desired target, such as human toxins, tumor cells or microbial pathogens.

XON believes the following companies engage in the manufacture of human or human-like monoclonal antibodies: AbD SeroTec (a Bio-Rad Laboratories, Inc. company), Alexion Pharmaceuticals, Inc., XOMA Corporation, Genmab US, Inc., MorphoSys AG, NovImmune SA, Société Des Systèmes Biologiques, or BIOTEM, Adimab, LLC, ProMab Biotechnologies, Inc., Abpro, Inc., AIIM Therapeutics and Open Monoclonal Technology, Inc.

• Industrial companies who may develop their own approach to synthetic biology. Large biopharmaceutical companies, energy companies, and ag-bio companies may pursue a proprietary synthetic biology strategy.

• Industrial companies who may develop competing products using other technologies. Large biopharmaceutical companies pursue other technologies for drug development, and large ag-bio companies pursue other technologies for the development of genetically modified crops.

5% stockholder pre-IPO

Randal J. Kirk, 71%

Use of proceeds

XON expects to net $113.5 million from its IPO.

Proceeds are allocated to further business development efforts to consummate new collaboration agreements with new companies across various commercial divisions, and for working capital and other general corporate purposes.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for XON
biotech 2050
27 Mar 15 00:26:56
@Biotech2050 $CELG $BLUE might need $ZIOP $XON to be very safe before going to clinic - Mark Alles last minute http://t.co/lPHcVabZgQ
biotech 2050
27 Mar 15 00:10:31
@pharmamaven @megtirrell M Alles of $CELG 23rd min http://t.co/lPHcVabZgQ Update $OMED $XLRN $BLUE maybe with $ZIOP $XON to improve safety?
Scott Thomas
26 Mar 15 23:47:32
RT @pharmamaven: @pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says s…
biotech 2050
26 Mar 15 23:19:29
RT @pharmamaven: @pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says s…
biotech 2050
26 Mar 15 23:10:23
@pharmamaven Could $CELG have set their eyes on #SELINEXOR $KPTI for #myeloma https://t.co/YqhKkNgqak Or as you on IV, eyes on $ZIOP $XON ?
26 Mar 15 21:19:06
Will it survive? Find out here: http://t.co/RSegwJ2fz2 $UPRO $GRPO $OCAT $IBB $HYG $ILMN $XON $ZIOP $GOOG $AAPL http://t.co/4OwK2rOIq1
26 Mar 15 19:47:15
RT @pharmamaven: @pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says s…
Thomas Anthony
26 Mar 15 19:29:58
RT @pharmamaven: @pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says s…
Jon Miarecki
26 Mar 15 19:24:19
RT @pharmamaven: @pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says s…
26 Mar 15 18:40:53
RT @pharmamaven: @pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says s…
Reggie Thomas
26 Mar 15 18:33:19
RT @pharmamaven: @pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says s…
26 Mar 15 17:51:46
RT @pharmamaven: @pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says s…
Kristina Duering
26 Mar 15 17:34:50
RT @pharmamaven: @pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says s…
26 Mar 15 17:26:51
@pharmamaven What if $CELG licensed Rheo Switch & all blood cancer indications from $ZIOP $XON @MDAndersonNews? RBC says something coming.
26 Mar 15 15:14:07
Stocks for the screener. $UPRO $GRPO $OCAT $IBB $HYG $ILMN $XON $ZIOP http://t.co/YU579z0Ece http://t.co/EUClslmBHz
Marty Milner
26 Mar 15 13:30:50
@herbgreenberg Herb any thoughts during closing bell on $XON?
26 Mar 15 12:46:04
$AEGR $AMCC $ARIA $BCRX $BDSI $BIB $CLDX $TXMD $XON autocharts @ http://t.co/cLiki3R0GR
26 Mar 15 12:40:24
$KIPS stock of the century compare to $XON on cnbc host. I am risking to lose .17c to make 500% in 2-3 years if ESVS trial @SheffStation
26 Mar 15 12:07:09
Will it survive? Find out here: http://t.co/RSegwJ2fz2 $UPRO $GRPO $OCAT $IBB $HYG $ILMN $XON $ZIOP $GOOG $AAPL http://t.co/UzxeygATrs
26 Mar 15 11:37:35
$ACAD $AEGR $AGIO $AKRX $ALKS $ARIA $GERN $WTW $XON autocharts @ http://t.co/cLiki3R0GR
26 Mar 15 11:21:35
$AGIO $ALKS $ALNY $AMAG $ARRY $SSE $VSTM $WBAI $XON autocharts @ http://t.co/cLiki3R0GR
Marty Milner
26 Mar 15 11:13:00
@herbgreenberg Any thoughts on $XON now? I still like your call-do you have an update? :-($)
Marty Milner
26 Mar 15 10:41:29
RT @pharmamaven: @martymilner @jimcramer $XON $ZIOP Chrm Kirk:"we have Best Technology Suite in CAR T Space"-"Major new alliances" http://t…
26 Mar 15 10:24:06
@canuck2usa I know you ignore TV, keep it on mute a lot myself but THINK I heard Bill Miller on Fri & if he loves $ZIOP & $XON (if rembr rt)
26 Mar 15 09:18:35
$AGIO $AKRX $ALNY $AMAG $AMRN $ANTH $ARRY $GERN $XON autocharts @ http://t.co/cLiki3R0GR
26 Mar 15 09:06:21
RT @pharmamaven: Loading Loading $CRMD $ZIOP $XON semi annual "biotech bubble" fear parade just like last 6 yrs.EVERY yr bio beats S&P for…
26 Mar 15 09:03:35
$ACAD $AKRX $ALNY $AMAG $AMBA $ARRY $GERN $VEEV $XON autocharts @ http://t.co/cLiki3R0GR
Scott Spencer
26 Mar 15 08:52:46
Short Interest Decreases By 11.8% For $XON http://t.co/dtGVGYz7U5
Scott Spencer
26 Mar 15 08:50:27
$XON added more at $38.75 LONG
biotech 2050
26 Mar 15 07:47:37
@BeantownBio $GILD will report #HARVONI #SOVALDI numbers; news from $CRMD; $HALO #PEGPH20 updates + $ZIOP $XON deals any time; $XLRN $OMED..
26 Mar 15 07:22:27
$AKRX $AMBA $ARIA $ARRY $ATML $GERN $LCI $OPK $XON autocharts @ http://t.co/cLiki48C5r
biotech 2050
26 Mar 15 06:53:48
26 Mar 15 06:17:43
The wall street whores are making sure they get their quarter end bonus checks. Locking down gains causing disuption $xon $ziop $cldn $juno
26 Mar 15 06:15:04
$XON: Intrexon Aquires an Arctic Apple That Doesn't Brown: http://t.co/1eGkbNFMMx
Rachel Smith
26 Mar 15 05:36:10
$XON - 3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy? http://t.co/9dyJsrSv0t
Suhail Ahmad
26 Mar 15 05:30:32
RT @SiAlpha: Stock Market Preview $XLE $XON $EXPE - http://t.co/PB5h2U8oE8 #Energy #Expedia #Oil #Saudi #Yemen
26 Mar 15 05:30:06
Stock Market Preview $XLE $XON $EXPE - http://t.co/PB5h2U8oE8 #Energy #Expedia #Oil #Saudi #Yemen
Breaking News
26 Mar 15 04:37:03
$XON: Biotech Stocks moved down: Juno Therapeutics , (NASDAQ:JUNO ...: http://t.co/KmuqmCdKJX
26 Mar 15 04:08:24
Watch the 10 week ma lines for end of quarter sell off support. $juno $cldn $qure $ziop $xon $blue $cmvlf etc. Wall st a rbs
26 Mar 15 02:55:06
Will it survive? Find out here: http://t.co/RSegwIKEas $UPRO $GRPO $OCAT $IBB $HYG $ILMN $XON $ZIOP $GOOG $AAPL http://t.co/w1gkTr0oPE
PennyStock Zone
25 Mar 15 20:21:57
http://t.co/C3NugKVycW <-- FREE access to a Tim Sykes premium video lesson usually only for subscribers! $UGAZ $DWTI $XON
25 Mar 15 18:12:07
Will it survive? Find out here: http://t.co/RSegwJ2fz2 $UPRO $GRPO $OCAT $IBB $HYG $ILMN $XON $ZIOP $GOOG $AAPL http://t.co/SWla2w1aZR
25 Mar 15 17:28:48
@wzpurdy $ONNN $CLDX $XON; i like your strategy here. weeklies or 2wk> ? $XON drop to 38.5 buy calls strike 42 or 40 http://t.co/cezgLD20Lu
25 Mar 15 17:02:25
watchlist for tomorrow: $ONN drop to 11.60 buy calls strike 12.5 $CLDX drop to 24.28 buy calls strike 28 or 26 $XON buy calls strike 43.50
25 Mar 15 15:13:08
Stocks for the screener. $UPRO $GRPO $OCAT $IBB $HYG $ILMN $XON $ZIOP http://t.co/YU579z0Ece http://t.co/jpccRHKFN3
Me Likeitalot
25 Mar 15 12:45:19
RT @VMichael44: $ZIOP $XON Feels like a Ziopharm & Big Pharm/Biotech tie up relatively soon either lucrative partnership or the other word,…
Me Likeitalot
25 Mar 15 12:45:08
RT @VMichael44: $ZIOP $XON Another comment CEO of Intrexon RJ Kirk made was 2015 would be very "Vindicating" for shareholders; doubt he mea…
Me Likeitalot
25 Mar 15 12:44:23
RT @pharmamaven: Added $CELG under 119, 10,000 $ZIOP under 11, $XON , and $CRMD (actually green expect a sale within a month by mgt/Elliot …
Me Likeitalot
25 Mar 15 12:25:42
@Asthika $ZIOP $HALO $XON $TGTX Yep, the ones doing most of the whining about it; calling a Bubble are the jealous ones that not own it!
Breaking News Now
25 Mar 15 12:20:03
$XON: Short Interest Decreases By 11.8% For XON: http://t.co/3yDCXP5SK9
By  +Follow August 7, 2013 11:03AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.